This meeting will bring experts on biosimilar medicines together with practitioners to discuss the development and commercialisation of biosimilars, which are off-patent versions of biologic drugs. The conference will discuss biosimilar manufacturing and commercialisation considerations specific to the US, featuring case studies of approved products. In March, the US Food and Drug Administration Commissioner Scott Gottlieb said that registering biosimilar medicines was a priority for the FDA.
